CORE-ABR
Sales sheet Request a demo

Pathogen

Staphylococcus aureus

The leading cause of skin and soft-tissue infection, and the organism most wound reports are built around.

Also: staph aureus, MRSA, MSSA

Gram-positive bacteriaUTI panelWound panelSTI panelGraded on the antibiogram

How CORE-ABR grades it

No clinically relevant intrinsic resistance to anti-staphylococcal agents. The grid is driven by detected genes: mecA / mecC removes the beta-lactams PBP2a defeats while keeping ceftaroline; tetB / tetM removes doxycycline and minocycline while sparing omadacycline and tigecycline; ermB / ermC removes clindamycin and the macrolides.

Try it on the home page: the interactive grid toggles mecA, tetB / tetM and ermB / ermC on an S. aureus wound specimen.

What the report shows for Staphylococcus aureus

  • Detected or not detected, with Ct, limit of detection and cycles above LOD — see PCR reporting.
  • A short pathogen summary, including colonizer likelihood where it applies.
  • A graded column on the antibiogram, and therapy options by scenario on the P.A.C.T. report.
  • When not detected, it is still listed among targets tested.

Resistance genes CORE-ABR applies

When detected, each of these genes is applied to Staphylococcus aureus only for the agents its mechanism defeats.

mecA / mecCMethicillin resistance (MRSA, MRSE)2 organisms on paneltetB / tetMTetracycline resistance9 organisms on panelermB / ermCMLSb resistance7 organisms on paneldfrA1 / dfrA5Trimethoprim resistance6 organisms on panel

Tagged

Decision support only. The treating clinician decides. Molecular genotype does not replace phenotypic susceptibility testing, culture, or public-health reporting. Absence of a detected resistance gene does not establish susceptibility. Organism targets vary by panel; CORE-ABR is configured to the assay each laboratory runs.